Cargando…

Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome

OBJECTIVES: To compare anti-inflammatory effect of atorvastatin and rosuvastatin in patients of acute coronary syndrome. MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 patients of acute coronary syndrome. Patients were assigned t...

Descripción completa

Detalles Bibliográficos
Autores principales: Khurana, Sushant, Gupta, Surabhi, Bhalla, HiraLal, Nandwani, Shefali, Gupta, Varad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544133/
https://www.ncbi.nlm.nih.gov/pubmed/26311995
http://dx.doi.org/10.4103/0976-500X.162011
_version_ 1782386646802497536
author Khurana, Sushant
Gupta, Surabhi
Bhalla, HiraLal
Nandwani, Shefali
Gupta, Varad
author_facet Khurana, Sushant
Gupta, Surabhi
Bhalla, HiraLal
Nandwani, Shefali
Gupta, Varad
author_sort Khurana, Sushant
collection PubMed
description OBJECTIVES: To compare anti-inflammatory effect of atorvastatin and rosuvastatin in patients of acute coronary syndrome. MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 patients of acute coronary syndrome. Patients were assigned to atorvastatin 40 mg daily or rosuvastatin 20 mg daily for 4 weeks. C-reactive protein (CRP) levels, lipid profiles, erythrocyte sedimentation rate (ESR) and adverse effects were measured at beginning and at the end of 4 weeks. RESULTS: Baseline parameters and clinical profile did not differ between the two groups. CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 ± 6.32 vs 23.07 ± 7.47, P < 0.05). In addition, both the drugs were associated with a reduction in total cholesterol, LDL levels and ESR at the end of 4 weeks as compared to the beginning (P < 0.001 for all comparisons). CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin was found to be more effective in decreasing CRP levels.
format Online
Article
Text
id pubmed-4544133
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-45441332015-08-26 Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome Khurana, Sushant Gupta, Surabhi Bhalla, HiraLal Nandwani, Shefali Gupta, Varad J Pharmacol Pharmacother Research Paper OBJECTIVES: To compare anti-inflammatory effect of atorvastatin and rosuvastatin in patients of acute coronary syndrome. MATERIALS AND METHODS: The study was a prospective, open-labeled, randomized and single-center study conducted on 100 patients of acute coronary syndrome. Patients were assigned to atorvastatin 40 mg daily or rosuvastatin 20 mg daily for 4 weeks. C-reactive protein (CRP) levels, lipid profiles, erythrocyte sedimentation rate (ESR) and adverse effects were measured at beginning and at the end of 4 weeks. RESULTS: Baseline parameters and clinical profile did not differ between the two groups. CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 ± 6.32 vs 23.07 ± 7.47, P < 0.05). In addition, both the drugs were associated with a reduction in total cholesterol, LDL levels and ESR at the end of 4 weeks as compared to the beginning (P < 0.001 for all comparisons). CONCLUSION: Both atorvastatin (40 mg) and rosuvastatin (20 mg) are effective in decreasing CRP and LDL cholesterol levels even in a short duration of 4 weeks. Rosuvastatin was found to be more effective in decreasing CRP levels. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4544133/ /pubmed/26311995 http://dx.doi.org/10.4103/0976-500X.162011 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Khurana, Sushant
Gupta, Surabhi
Bhalla, HiraLal
Nandwani, Shefali
Gupta, Varad
Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
title Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
title_full Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
title_fullStr Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
title_full_unstemmed Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
title_short Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
title_sort comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544133/
https://www.ncbi.nlm.nih.gov/pubmed/26311995
http://dx.doi.org/10.4103/0976-500X.162011
work_keys_str_mv AT khuranasushant comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome
AT guptasurabhi comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome
AT bhallahiralal comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome
AT nandwanishefali comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome
AT guptavarad comparisonofantiinflammatoryeffectofatorvastatinwithrosuvastatininpatientsofacutecoronarysyndrome